

THE EU RESEARCH & INNOVATION PROGRAMME 2021 - 2027

Gene-editing platform for safer cell-therapies


Dr. Yoel Shiboleth, CEO and co-founder

TargetGene Biotechnologies (SME)

Israel

yoel@targetgenebio.com

https://targetgenebio.com





TargetGene is solving "off target"- gene-editing's safety problem

FDA's Genome Editing draft guidance for industry emphasizes "off-target" as a risk

Obligatory dimerization with two guide RNAs can reduce "off-target" to virtually zero


Human Gene Therapy Products Incorporating Human Genome Editing

March 16th 2022

- ... "Some of the specific risks associated with GE approaches include off-target editing, unintended consequences of on- and off-target editing, and the unknown long term effects of on- and off-target editing. "...
- ... "We recommend sponsors optimize the GE components to reduce the potential for off-target genome modification, to the extent possible.

 Optimization can be performed on the editor or the targeting elements, depending on the GE technology being utilized". [emphasis added]...






Active dimeric nuclease


cuts both strands of target DNA allowing Deletion, Insertion or Replacement

Reduction of off-target genome modification is a distinct advantage of T-GEE



TargetGene is genetically rewiring the cell with gene-editing







Granted consortium 2023













Seeking partners

Will consider providing gene-editing solutions to any application with therapeutic potential, to develop:

- Specific disease indications (i.e. Cancer, hematological, cardiovascular, autoimmune, heritable disease, etc.)
- Novel targets and pathways, disease models
- Delivery modalities (i.e virus-free, EVs, ...)
- Cell types (HSCs, immune-cells, TILs, iPSCs, ...)
- Cell Products (i.e. ex-vivo, allogeneic, autologous, ...)
- Commercial production (automated, GMP, batch, continuous...)





THE EU RESEARCH & INNOVATION PROGRAMME 2021 - 2027

T-GEE is a superior gene-editing technology



Contact us

https://targetgenebio.com

